Richard W Yee

Richard W. Yee, M.D., P.A. is a Houston-based clinical research and ophthalmic practice specializing in the diagnosis and treatment of complex ocular surface diseases. Led by Dr. Richard W. Yee, a prominent corneal specialist and researcher, the organization serves as a high-volume clinical trial site for leading pharmaceutical and biotechnology companies. The entity is particularly noted for its expertise in dry eye disease (DED), Meibomian Gland Dysfunction (MGD), and Demodex blepharitis, having played a key role in the clinical development of various FDA-approved ophthalmic therapies such as Lotilaner. Beyond clinical services, the organization develops and evaluates novel diagnostic technologies, including tear film interferometry and meibography, often in collaboration with its affiliate, C-Sight, Inc. Dr. Yee's extensive patent portfolio and academic contributions have established the practice as a center of excellence for ophthalmic innovation.